- জেনেরিক নাম
- Ibandronic Acid
- শক্তি
- 3 mg/3 ml
- ডোজ ফর্ম
- IV Infusion
- প্রস্তুতকারক
- Healthcare Pharmaceuticals Ltd.
- থেরাপিউটিক ক্লাস
- Bisphosphonate preparations
৳ ৪৪১০ ৳ ৪৫০০.০০ ২% ছাড় প্রতি ইউনিট
দাম হালনাগাদ: ১৮ Nov ২০২৬
Bondrova 3 mg/3 ml IV Infusion একটি IV Infusion ঔষধ, যার জেনেরিক নাম Ibandronic Acid এবং শক্তি ৩ mg/৩ ml। Bondrova-এর প্রতি ইউনিটের দাম ৪৫০০.০০ টাকা। ঔষধটি Bisphosphonate preparations শ্রেণির অন্তর্ভুক্ত। এটি তৈরি করে Healthcare Pharmaceuticals Ltd। Bondrova-এর সাথে Ibandronic Acid-এর অন্য ব্র্যান্ডের দাম নিচে তুলনা করে দেখুন। এই তথ্য শুধু জানার জন্য; ঔষধ সবসময় ডাক্তারের পরামর্শ অনুযায়ী খাবেন, মাত্রা বা ব্র্যান্ড নিয়ে প্রশ্ন থাকলে ফার্মাসিস্টকে জিজ্ঞেস করুন।
Ibandronic Acid-এর ১৩টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত। এর চেয়ে কম ইউনিট দামের ব্র্যান্ড আছে ১০টি। সবচেয়ে কম দাম Bondrix 150 mg Tablet-এর, প্রতি ইউনিট ৳ ৪০০.০০।
Made by Healthcare Pharmaceuticals Ltd., Bondrova is a iv infusion whose active ingredient is Ibandronic Acid. The doctor confirms the diagnosis and decides whether this medicine is suitable. Ibandronic Acid works by slowing bone resorption. Ask your doctor or pharmacist if you are unsure about it.
The doctor may confirm it with a bone density scan and a history of fracture. The doctor reviews the test results and the patient's history before prescribing it. Ask the doctor if you are unsure why it has been prescribed for you or what it is expected to do in your case. Your doctor will decide if it is suitable for you.
It is not for self-administration. If you miss a dose, ask your doctor or pharmacist what to do. Do not change the dose or stop early without asking your doctor.
Serious problems are uncommon, but any new or worrying symptom should be checked by your doctor. Some people may notice indigestion, nausea, diarrhoea, abdominal pain, muscle aches, headache or dizziness after taking Bondrova. Any unusual or severe reaction should be reported to a healthcare professional promptly. Tell your doctor if these bother you or do not settle. Tell your doctor or pharmacist if you experience any of these or other unusual symptoms.
Pregnancy : Ibandronic Acid should not be used during pregnancy. Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when Ibandronic Acid is given to patients with active upper gastrointestinal problems (e.g. As with several bisphosphonates, Ibandronic Acid is contraindicated in patients with abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia. Ask your doctor first if any of these apply to you.
The doctor may confirm it with a bone density scan and a history of fracture. The doctor reviews the test results and the patient's history before prescribing it.
It is not for self-administration. If you miss a dose, ask your doctor or pharmacist what to do.
Serious problems are uncommon, but any new or worrying symptom should be checked by your doctor. Some people may notice indigestion, nausea, diarrhoea, abdominal pain, muscle aches, headache or dizziness after taking Bondrova.
The listed price is ৳ ৪৫০০.০০.
৳ ৪৪১০ ৳ ৪৫০০.০০ ২% ছাড় প্রতি ইউনিট
দাম হালনাগাদ: ১৮ Nov ২০২৬
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Ibandronic acid is indicated for the treatment of postmenopausal osteoporosis, to reduce the risk of fractures.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
The pharmacodynamic action of ibandronic acid is inhibition of bone resorption. In vivo, ibandronic acid prevents experimentally induced bone destruction caused by cessation of gonadal function, retinoids, tumors or tumor extracts. In young (fast growing) rats, the endogenous bone resorption is also inhibited, leading to increased bone mass compared with untreated animals. Animal models confirm that ibandronic acid is a highly potent inhibitor of osteoclastic activity. In growing rats, there was no evidence of impaired mineralization even at doses greater than 5,000 times the dose required for osteoporosis treatment. The high potency and therapeutic margin of ibandronic acid allows for more flexible dosing regimens and intermittent treatment with long drug-free intervals at comparatively low doses.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
The recommended dose of Ibandronic acid for treatment is one 150 mg film-coated tablet once a month. The tablet should preferably be taken on the same date each month. Ibandronic acid should be taken 60 minutes before the first food or drink (other than water) of the day or any other oral medication or supplementation (including calcium):এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
It is likely that calcium supplements, antacids and some oral medications containing multivalent cations (such as aluminium, magnesium, iron) are likely to interfere with the absorption of Ibandronic Acid. Therefore, patients must wait 60 minutes after taking Ibandronic Acid before taking other oral medications. Pharmacokinetic interaction studies in postmenopausal women have demonstrated the absence of any interaction potential with tamoxifen or hormone replacement therapy (estrogen). No interaction was observed when co-administered with melphalan/prednisolone in patients with multiple myeloma. In healthy male volunteers and postmenopausal women, i.v. ranitidine caused an increase in ibandronic acid bioavailability of about 20 %, probably as a result of reduced gastric acidity. However, since this increase is within the normal range of the bioavailability of ibandronic acid, no dosage adjustment is required when Ibandronic Acid is administered with H2-antagonists or other drugs which increase gastric pH.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Ibandronic Acid is contraindicated in patients with known hypersensitivity to ibandronic acid or to any of the excipients. Ibandronic Acid is contraindicated in patients with uncorrected hypocalcemia. As with all bisphosphonates indicated in the treatment of osteoporosis, pre-existing hypocalcemia needs to be corrected before initiating therapy with Ibandronic Acid. As with several bisphosphonates, Ibandronic Acid is contraindicated in patients with abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia. Ibandronic Acid is contraindicated in patients who are unable to stand or sit upright for at least 60 minutes.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
The main side effects of ibandronic acid are dyspepsia, nausea, diarrhea, abdominal pain, muscle aches, headaches, dizziness.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Pregnancy: Ibandronic Acid should not be used during pregnancy. There was no evidence for a direct fetal toxic or teratogenic effect of ibandronic acid in daily orally treated rats and rabbits and there were no adverse effects on the development in F1 offspring in rats. Adverse effects of ibandronic acid in reproductive toxicity studies in the rat were those observed with bisphosphonates as a class. They include a decreased number of implantation sites, interference with natural delivery (dystocia), and an increase in visceral variations (renal pelvis ureter syndrome). Specific studies for the monthly regimen have not been performed. There is no clinical experience with Ibandronic Acid in pregnant women.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Ibandronic Acid therapy. Adequate intake of calcium and vitamin D is important in all patients. Orally administered bisphosphonates may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when Ibandronic Acid is given to patients with active upper gastrointestinal problems (e.g. known Barrett’s esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis or ulcers). Adverse experiences such as esophagitis, esophageal ulcers and esophageal erosions, in some cases severe and requiring hospitalization, rarely with bleeding or followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates. The risk of severe esophageal adverse experiences appears to be greater in patients who do not comply with the dosing instruction and/or who continue to take oral bisphosphonates after developing symptoms suggestive of esophageal irritation. Patients should pay particular attention and be able to comply with the dosing instructions.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
No specific information is available on the treatment of overdosage with ibandronic acid. However, oral overdosage may result in upper gastrointestinal adverse events, such as upset stomach, heartburn, esophagitis, gastritis, or ulcer. Milk or antacids should be given to bind ibandronic acid. Owing to the risk of esophageal irritation, vomiting should not be induced and the patient should remain fully upright.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।
ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।